Welcome to our dedicated page for Dexcom news (Ticker: DXCM), a resource for investors and traders seeking the latest updates and insights on Dexcom stock.
Dexcom Inc (DXCM) is a leader in continuous glucose monitoring systems, transforming diabetes care through real-time health data solutions. This page consolidates official announcements, financial updates, and strategic developments for stakeholders tracking the company’s progress in medical technology.
Access timely updates on product innovations, regulatory milestones, and partnership agreements that shape Dexcom’s position in the diabetes management sector. Investors will find earnings reports and market analyses, while healthcare professionals can monitor clinical trial outcomes and device enhancements.
Key content includes FDA clearances, international expansion updates, and technology integration developments with insulin delivery systems. All materials are sourced from verified channels to ensure reliability for research and decision-making.
Bookmark this page for streamlined access to Dexcom’s latest advancements in CGM technology and related financial performance. Check regularly for critical updates that impact both patient care and investment considerations.
DexCom, Inc. (NASDAQ:DXCM) has announced that Jereme Sylvain, Executive Vice President and CFO, will present updates at two upcoming investor conferences. The first is the BofA Securities 2022 Healthcare Conference on May 11, 2022, at 5:40 PM (EST), and the second is the William Blair 42nd Annual Growth Stock Conference on June 8, 2022, at 5:00 PM (EST). Webcasts for these events will be available on the DexCom Investor Relations website and archived for future access.
DexCom announces an update regarding its first quarter 2022 earnings call, rescheduling it to start at 5:30 p.m. ET due to technical difficulties with the conference call provider. The link for the webcast will be available on the DexCom investor relations website and will be archived for future reference. Investors can listen to the call by dialing the provided numbers and using the confirmation number.
DexCom continues to focus on empowering diabetes management through innovative continuous glucose monitoring (CGM) systems, emphasizing its leadership in diabetes care technology.
DexCom, Inc. (Nasdaq: DXCM) reported a 25% revenue growth in Q1 2022, reaching $628.8 million. U.S. revenue rose 18% while international revenue surged 43%. GAAP operating income was $41.3 million (6.6% of revenue), down from the previous year. The company reaffirmed its 2022 revenue guidance of $2.82 - 2.94 billion and outlined strategic initiatives, including the limited launch of the Dexcom G7 in Europe and new market expansions. Cash reserves stood at $2.69 billion, providing strong financial flexibility.
DexCom, the leader in continuous glucose monitoring (CGM), introduced its new product portfolio at the ATTD conference, showcasing the Dexcom ONE, Dexcom G6, and the FDA-reviewed Dexcom G7. These systems aim to enhance diabetes management with features like real-time monitoring and customizable alerts. The Dexcom ONE is now accessible in Spain and will launch in the UK this May. The offerings emphasize innovation and connectivity, designed to cater to diverse diabetes needs.
DexCom, Inc. (NASDAQ:DXCM) announced that its new Dexcom ONE Continuous Glucose Monitoring System will launch in the UK this May. Currently under review for addition to the NHS Drug Tariff, this system aims to enhance accessibility for diabetes management. The NICE has recommended offering glucose sensors to Type 1 diabetes patients based on individual needs, promoting better health outcomes. Dexcom ONE features a user-friendly app for real-time glucose monitoring, reducing the need for fingerpricks and improving treatment decisions.
DexCom, Inc. (NASDAQ:DXCM) announced plans to release its first quarter 2022 financial results after the market closes on Thursday, April 28, 2022. A conference call will be held at 4:30 p.m. (ET) to discuss the results, with a live webcast available on the investor relations website.
DexCom, based in San Diego, California, is a leader in continuous glucose monitoring systems, aiming to improve diabetes management globally.
Dexcom, Inc. (NASDAQ:DXCM) announced a four-for-one forward stock split, pending stockholder approval for an increase in authorized shares from 200 million to 800 million. If approved, each share outstanding on May 19, 2022, will split into four shares. The split-adjusted trading is set to commence on June 10, 2022. This action aims to enhance stock liquidity and accessibility for investors. Further details will be provided in the Preliminary Proxy Statement filed with the U.S. Securities and Exchange Commission on March 25, 2022.
DexCom (NASDAQ:DXCM) has received CE Mark approval for its Dexcom G7 Continuous Glucose Monitoring (CGM) system, enhancing diabetes management for users aged two and older in Europe. The Dexcom G7 features the market's fastest sensor warmup at 30 minutes, a compact design, and a redesigned mobile app that integrates Dexcom Clarity. This system eliminates the need for fingersticks, providing real-time glucose data directly to smart devices. DexCom plans to launch the G7 in Europe shortly, further solidifying its leadership in real-time CGM technology.
Dexcom announced CE Mark approval for its G7 Continuous Glucose Monitoring (CGM) System, enhancing diabetes management for users in Europe aged two years and older, including pregnant women. The G7 is designed to be more powerful and user-friendly, with a 30-minute sensor warmup time, no fingersticks required, and real-time glucose readings sent to compatible devices. The system reduces blood sugar fluctuations and increases time in range, supporting better health outcomes.
FAQ
What is the current stock price of Dexcom (DXCM)?
What is the market cap of Dexcom (DXCM)?
